Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer

Tetsuji Moriya, Masatsugu Hamaji, Akihiko Yoshizawa, Ryo Miyata, Misa Noguchi, Shige Yuki Tamari, Naohisa Chiba, Hideaki Miyamoto, Toshiya Toyazaki, Satona Tanaka, Yoshito Yamada, Yojiro Yutaka, Daisuke Nakajima, Akihiro Ohsumi, Toshi Menju and Hiroshi Date

Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan

* Corresponding author. Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel: +81-75-7514975; fax: +81-75-7514974; e-mail: mhamaji@kuhp.kyoto-u.ac.jp (M. Hamaji).

Received 25 May 2021; received in revised form 10 August 2021; accepted 20 September 2021

Abstract

OBJECTIVES: To clarify survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) as first-line treatment for postoperative recurrence.

METHODS: A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of non-small-cell lung cancer (NSCLC) harbouring EGFR gene mutations at our institution between August 2002 and October 2020. Therapeutic response, adverse events, progression-free survival (PFS) and overall survival (OS) were investigated.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Survival outcomes were assessed using the Kaplan–Meier analysis. The Cox proportional hazards model was used for univariable and multivariable analyses.

RESULTS: Sixty-four patients were included in the study. The objective response and disease control rates were 53% and 92%, respectively. Grade 3 or greater adverse events were noted in 4 (6.3%) patients, including 1 patient (1.6%) of interstitial pneumonia. The median follow-up period was 28.5 months (range 3–202 months). The total number of events was 43 for PFS and 23 for OS, respectively. The median PFS was 18 months, and the median OS was 61 months after EGFR-TKI treatment. In multivariable analysis, osimertinib showed a tendency to prolong PFS [hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.12–1.1; P = 0.071], whereas the micropapillary component was significantly associated with shorter OS (HR 2.1, 95% CI 1.02–6.9; P = 0.045).

CONCLUSIONS: EGFR-TKIs as first-line treatment appeared to be a reasonable treatment option in selected patients with postoperative recurrent EGFR-mutated NSCLC. Osimertinib and the micropapillary component may be prognostic factors.

Keywords: Lung cancer • Epidermal growth factor receptor • Postoperative recurrence

ABBREVIATIONS

| Abbreviation | Definition          |
|--------------|---------------------|
| CI           | Confidence interval |
| CT           | Computed tomography |
| EGFR         | Epidermal growth factor receptor |
| HR           | Hazard ratio        |
| NSCLC        | Non-small-cell lung cancer |
| OS           | Overall survival    |
| PD           | Progressive disease |
| PFS          | Progression-free survival |
| TKI          | Tyrosine kinase inhibitor |

INTRODUCTION

Epidermal growth factor receptor (EGFR) mutations are well-established oncogenic targets for management of advanced-stage non-small-cell lung cancer (NSCLC) [1, 2]. According to the guidelines provided by the Japan Lung Cancer Society, European Society of Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN), EGFR-tyrosine kinase inhibitors (TKIs) are recommended as the first-line treatment for stage IV NSCLC harbouring EGFR gene mutations, whereas there is a dearth of data on postoperative recurrent stage IV patients in practice-based settings [3–6].

Specifically, recent clinical trials for patients with advanced and EGFR-mutated NSCLC demonstrated objective response rates ranging from 63% to 80%, disease control rates of >90% and grade 3 or greater adverse events ranging from 9% to 50% as short-term outcomes [6–11]. Regarding long-term survival outcomes in those trials, median progression-free survival (PFS) ranged from 8 to 11 months in patients receiving first- or second-generation EGFR-TKIs and >18 months in those receiving third-generation EGFR-TKIs as first-line therapy [7–10]. However, it is unknown whether recommendations from the above guidelines and findings from these trials can be translated into patients with postoperative recurrence because patients with postoperative recurrence may be older, more morbid, associated with a more complicated history of illness and poorer cardiopulmonary function than the patients enrolled in the clinical trials [6, 12].

The aim of this study was to investigate the short-term and long-term outcomes and management of patients receiving first-line EGFR-TKI for postoperative recurrence of NSCLC harbouring EGFR gene mutations and to elucidate potential prognostic factors associated with favourable (or poor) survival outcomes in these patients.

PATIENTS AND METHODS

This study was approved by the Institutional Review Board of Kyoto University Hospital (reference number: R2504, approval date: 22 June 2020). The requirement for informed patient consent was waived. This retrospective observational study was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (Supplementary Material, Table S1) [13]. This study was performed in accordance with the Declaration of Helsinki (1975, as revised in 2013) and Good Clinical Practice guidelines (as defined by the International Conference on Harmonization).

A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of NSCLC harbouring EGFR gene mutations at our hospital between August 2002 and October 2020. The patients must be within grade 0–2 on the Eastern Cooperative Oncology Group (ECOG) scale of performance status at the beginning of medication. We excluded patients who had any distant metastasis at the initial surgery and those who received cytotoxic chemotherapy as a first-line treatment for postoperative recurrence.

Pathological staging was classified according to the International System for Staging Lung Cancer by the eighth edition. NSCLC histology was classified according to World Health Organization classification. EGFR gene mutations in exons 18, 19, 20 and 21 were analysed in resected specimens at the initial surgery.

Management of epidermal growth factor receptor-tyrosine kinase inhibitors and follow-up

Types of EGFR-TKIs (first-, second- or third-generation) were selected after discussions at the multidisciplinary thoracic oncology board of our hospital. Gefitinib was usually administered at a dose of 250 mg/day daily, erlotinib at a dose of 150 mg/day daily, afatinib at a dose of 40 mg/day daily and osimertinib at a dose of 80 mg/day daily. The dose was reduced or discontinued at the attending physician’s discretion regarding toxicity. Chest and abdominal computed tomography (CT) scans were typically obtained within 3–6 months after the introduction of TKIs for the assessment of efficacy. Outpatient follow-up was generally set up every 1–3 months. Brain magnetic resonance imaging was obtained on an as-needed basis, although it was not routinely obtained if patients were asymptomatic. When progressive disease (PD) was suspected, additional examinations were
Table 1: Characteristics of the 64 patients who received EGFR-TKIs as a first-line therapy for postoperative recurrent and EGFR-mutated NSCLC

| Variables                                      | Grade 1 (n = 31), n (%) | Grade 2 (n = 34), n (%) | Grade 3 (n = 4), n (%) |
|------------------------------------------------|-------------------------|-------------------------|------------------------|
| EGFR gene mutations, n (%)                    |                         |                         |                        |
| Exon 21 point mutation                        | 32 (50)                 | 4 (6.3)                 |                         |
| Exon 19 deletion                               | 27 (42.2)               | 14 (21.9)               |                         |
| Exon 18 point mutation                         | 4 (6.3)                 |                         |                        |
| Exon 20 point mutation                         |                         |                         |                        |
| PD-L1 protein expression in the primary lesion, n (%) |                         |                         |                        |
| >50% positive                                  | 4 (6.3)                 |                         |                        |
| 1−49% positive                                 | 14 (21.9)               |                         |                        |
| Negative                                       | 7 (11)                  |                         |                        |
| Unknown                                        | 39 (61)                 |                         |                        |
| EGFR-TKIs, n (%)                               |                         |                         |                        |
| Gefitinib (first-generation)                   | 35 (55)                 |                         |                        |
| Erlotinib (second-generation)                  | 7 (11)                  |                         |                        |
| Aftatinib (second-generation)                  | 6 (9)                   |                         |                        |
| Osimertinib (third-generation)                 | 16 (25)                 |                         |                        |
| DFI (months), median (interquartile range)     | 15.5 (9–29)             |                         |                        |

DFI: disease-free interval; EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer; PD-L1: programmed death-ligand 1; TKI: tyrosine kinase inhibitor; TNM: tumour, node and metastasis.

Table 2: Adverse events in association with EGFR-TKIs as a first-line treatment in this study

| Variables                                      | Grade 1 (n = 31), n (%) | Grade 2 (n = 34), n (%) | Grade 3 (n = 4), n (%) |
|------------------------------------------------|-------------------------|-------------------------|------------------------|
| Rash or acne                                   | 16 (25)                 | 18 (28.1)               |                        |
| Diarrhoea                                      | 2 (3.1)                 | 8 (12.5)                |                        |
| Elevation of hepatic transaminases             | 5 (7.8)                 | 4 (6.3)                 |                        |
| Paronychia                                     | 2 (3.1)                 | 3 (4.7)                 |                        |
| Nausea                                         | 2 (3.1)                 |                         |                        |
| Thrombocytopenia                               | 1 (1.6)                 |                         |                        |
| Haemoptysis                                    | 1 (1.6)                 |                         |                        |
| Malaise                                        | 1 (1.6)                 |                         |                        |
| Haematuria                                     | 1 (1.6)                 |                         |                        |
| Fever                                          | 1 (1.6)                 |                         |                        |
| Epistaxis                                      | 1 (1.6)                 |                         |                        |

Responding and partial response. The disease control rate was the sum of complete response, partial response and stable disease. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). PFS was calculated from EGFR-TKI until the date of PD or death, or until the date the patient was last known to be alive and progression-free. Overall survival (OS) was calculated from EGFR-TKI until the date of death from any cause or until the date on which the patient was last known to be alive. The last follow-up date was 15 April 2021.

Statistical analysis

Based on the statistical and data-reporting guidelines of the European Journal of Cardiothoracic Surgery and Interactive Cardiovascular and Thoracic Surgery [14], descriptive statistics were reported as frequencies and percentages for categorical variables, and as medians and interquartile ranges for continuous variables. The collected data included age, sex, operative procedures, extent of resection, pathological stage in the eighth edition, tumour histology and histopathological subtypes, type of EGFR gene mutation, type of EGFR-TKIs used, site and number of recurrent lesions, adverse effects, disease-free interval and follow-up information until death or April 2021. We did not attempt to replace missing data and included all patients in the analyses using the available data. Survival curves were estimated using the Kaplan-Meier method. The Cox proportional hazards model was used for univariable and multivariable analyses, and the hazard ratios (HRs) were calculated. If a P-value was <0.15 on univariable analysis, it was included in the multivariable analysis. We did not correct for multiple testing in any of the tests performed. When the P-value was <0.05, it was considered statistically significant. All comparisons were two-sided. All statistical analyses were performed using JMP software (version 15.2; SAS Institute, Cary, NC, USA).

RESULTS

Sixty-four patients were included in this study. The median age was 70.5 years and 29 (45.3%) patients were male. The characteristics of the 64 eligible patients are shown in Table 1.

Short-term and long-term outcomes

In this study, the therapeutic response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) and was recorded based on the CT scan obtained within 3–6 months of initiating EGFR-TKIs. The response rate was the sum of the complete

scheduled, including re-biopsy (to examine T790M mutation) and positron emission tomography.
Responses to epidermal growth factor receptor-tyrosine kinase inhibitors and adverse events

Complete response and partial response were achieved in 3 (4.7%) and 31 (48.4%) patients, respectively. Stable disease was obtained in 25 patients (39.1%). The objective response rate was 53% and the disease control rate was 92%.

Adverse events in this study were summarized in Table 2. Any adverse event was noted in 57 patients (89%). Grade 3 or greater adverse events were confirmed in 4 patients (6.3%), including interstitial pneumonitis (n = 1), gastrointestinal bleeding (n = 1), thrombocytopenia (n = 1) and neutropenia (n = 1). The patient with interstitial pneumonia was treated with steroid pulse therapy and recovered steadily. Reduction in dosage or discontinuation of the first-line EGFR-TKI within the first 6 months due to side effects was noted in 31 (48.4%) patients, including 7 (10.9%) patients who switched to another EGFR-TKI.

Survival outcomes

The median follow-up period was 28.5 months (range 3–202 months). The total number of events was 43 for PFS and 23 for OS, respectively. The median PFS and OS of all patients after the initiation of EGFR-TKIs were 18 and 61 months, respectively. The 3- and 5-year PFS rates were 22.5% and 12.9%, respectively (Fig. 1A), and the 3- and 5-year OS rates were 71.3% and 51.5%, respectively (Fig. 1B). Univariable and multivariable analyses of potentially relevant factors associated with PFS and OS were shown in Tables 3 and 4, respectively. In univariable analysis, the disease-free interval [HR 0.20, 95% confidence interval (CI) 0.02–1.06; P = 0.060], no solid component (HR 0.61, 95% CI 0.32–1.1; P = 0.12) and third-generation TKI versus first- or second-generation TKI (HR 0.41, 95% CI 0.15–1.2; P = 0.10) showed tendencies to prolong PFS (Fig. 2A); in multivariable analysis, third-generation TKI versus first- or second-generation TKI (HR 0.41, 95% CI 0.15–1.2; P = 0.10) showed tendencies to prolong PFS. In univariable analysis, the micropapillary component (HR 2.9, 95% CI 1.2–7.5; P = 0.016) was a statistically significant factor associated with shorter OS (Fig. 2B), and disease-free interval (HR 0.06, 95% CI 0.001–1.35; P = 0.12) and pathological stage III versus stage I or II at initial surgery (HR 2.1, 95% CI 0.88–5.2; P = 0.091) showed a tendency to shorten OS. In multivariable analysis, the micropapillary component (HR 2.1, 95% CI 1.02–6.9; P = 0.045) was a statistically significant factor associated with shorter OS.

Management of progressive disease after first-line epidermal growth factor receptor-tyrosine kinase inhibitor

During the follow-up period, PD was observed in 39 patients. Among them, 21 (53.8%) patients switched to another TKI, 10 (25.6%) patients underwent cytotoxic chemotherapy (3 patients received single-agent pemetrexed, 3 patients received single-agent docetaxel, 2 patients received carboplatin, paclitaxel, bevacizumab and atezolizumab, 1 patient received carboplatin and nab-paclitaxel and 1 patient received carboplatin, pemetrexed and bevacizumab), 2 patients underwent salvage surgery (for pulmonary metastasis in both patients) and 2 patients received palliative radiotherapy only. The association between first-line EGFR-TKI and second-line management is summarized in Table 5, with third-generation TKI (osimertinib) being the most common TKI as second-line TKI in 13 patients. Re-biopsy to confirm T790M mutation was typically performed before switching to osimertinib after 2015.

After the introduction of osimertinib as a first-line EGFR-TKI, 3 patients were found to have PD. Two of these received carboplatin, paclitaxel, bevacizumab and atezolizumab as second-line therapy, and the other patient received carboplatin and nab-paclitaxel.

DISCUSSION

After curative or complete resection of NSCLC, 30–40% are known to recur [15, 16]; however, there have been few studies on
Our major findings were that osimertinib, a third-generation EGFR-TKI, compared to first- and second-generation TKIs, showed a tendency to extend PFS and that the micropapillary component was significantly associated with shorter OS after recurrence. The former finding was consistent with those from the FLAURA trial, and the latter may be a novel finding for patients with EGFR-mutated NSCLC.

Very few data are available on the association between adenocarcinoma subtypes and responses to EGFR-TKIs [21]. Previous studies suggested that the micropapillary component as a histological subtype appeared to be associated with postoperative recurrence in patients with EGFR-mutated lung adenocarcinoma [22, 23]. It was largely unknown whether micropapillary components may predict the response of recurrent lesions to EGFR-TKIs in these patients. Interestingly, our findings suggested that EGFR-mutated adenocarcinoma with micropapillary components may not respond to treatment with EGFR-TKIs. It was previously not demonstrated because relatively small specimens obtained by transbronchial or CT-guided biopsy may theoretically be less sensitive in identifying micropapillary components than surgical specimens. We emphasize that the findings are preliminary and require further studies because the histology was obtained at the time of initial pulmonary resection and not at recurrence in a majority of patients.

Management of PDs after EGFR-TKI therapy may play an important role in maintaining the quality of life or extending survival for patients receiving EGFR-TKIs. In this study, 39 (60.9%) patients had PD after EGFR-TKI, and a majority of them underwent treatments for PDs, which ranged from salvage surgery to cytotoxic chemotherapy, with switching to another EGFR-TKI such as osimertinib being the most frequent pattern, where resection with EGFR-TKIs may extend survival in patients with postoperative recurrence of EGFR-mutated lung adenocarcinoma [18].

Current recommendations of the guidelines derived from previous randomized controlled trials examining the effect of EGFR-TKIs on advanced-stage patients without separating newly diagnosed and postoperative recurrent NSCLCs [7, 19, 20]. Specifically, data from the FLAURA trial appeared to be the most updated on recent patients receiving EGFR-TKIs for advanced and EGFR-mutated NSCLC. However, there are several challenges in translating the data into patients with postoperative recurrence in a practice-based setting. There was no description of the number of patients with postoperative recurrence enrolled in the study. It should also be noted that patient characteristics in the FLAURA trial may differ from those in real-world data. In our study, compared to the FLAURA trial, patients tended to be older, included more males and more Asian patients, and included fewer patients with brain metastasis.

Our major findings were that osimertinib, a third-generation EGFR-TKI, compared to first- and second-generation TKIs, showed a tendency to extend PFS and that the micropapillary component was significantly associated with shorter OS after recurrence. The former finding was consistent with those from the FLAURA trial, and the latter may be a novel finding for patients with EGFR-mutated NSCLC.

Very few data are available on the association between adenocarcinoma subtypes and responses to EGFR-TKIs [21]. Previous studies suggested that the micropapillary component as a histological subtype appeared to be associated with postoperative recurrence in patients with EGFR-mutated lung adenocarcinoma [22, 23]. It was largely unknown whether micropapillary components may predict the response of recurrent lesions to EGFR-TKIs in these patients. Interestingly, our findings suggested that EGFR-mutated adenocarcinoma with micropapillary components may not respond to treatment with EGFR-TKIs. It was previously not demonstrated because relatively small specimens obtained by transbronchial or CT-guided biopsy may theoretically be less sensitive in identifying micropapillary components than surgical specimens. We emphasize that the findings are preliminary and require further studies because the histology was obtained at the time of initial pulmonary resection and not at recurrence in a majority of patients.

Management of PDs after EGFR-TKI therapy may play an important role in maintaining the quality of life or extending survival for patients receiving EGFR-TKIs. In this study, 39 (60.9%) patients had PD after EGFR-TKI, and a majority of them underwent treatments for PDs, which ranged from salvage surgery to cytotoxic chemotherapy, with switching to another EGFR-TKI such as osimertinib being the most frequent pattern, where rebiopsy to examine T790M mutation plays an important role.

In 2015, we started re-biopsy to examine T790M mutation before switching to osimertinib in 2015, as recommended in the guidelines from Japanese Lung Cancer Society. Before 2015, no patient
switched from first-generation or second-generation EGFR-TKIs to osimertinib (third-generation EGFR-TKI) or benefitted from osimertinib as second-line therapy for PD after first-line EGFR-TKI.

Osimertinib is a third-generation EGFR-TKI, and it remains unknown what the best management is for PD after first-line osimertinib. Our treatment of choice was cytotoxic chemotherapy with or without immune checkpoint inhibitors, whereas our data are too immature to estimate long-term outcomes. Currently, an increasing number of patients appear to have received osimertinib, rather than first- or second-generation EGFR-TKIs, the management of PD after osimertinib would be the next challenge of interest. Nivolumab, which is an immune checkpoint inhibitor, may be a treatment of choice for disease progression after EGFR-TKI in selected patients [24, 25]; however, the median PFS was from 1 to 2 months, and more data are required to identify patient groups that benefit from immune checkpoint inhibitors after EGFR-TKIs.

Limitations

The limitations of our study include its retrospective design, single-centre experience and sample size in a relatively large time frame. Selection of first-line or second-line EGFR-TKI was subject to physician’s preference; therefore, selection bias, which is inevitable due to the study design, could be another limitation. The diagnosis of postoperative recurrence was typically made based on radiological findings and not always on biopsies. Our patient cohort ranged from 2002 to 2020 at the time of initiating EGFR-TKIs, and several changes in management should have occurred. Especially at the beginning of our series, indications for EGFR-TKIs were not established from the guidelines. Specifically, it was not until 2014 that the guidelines from Japanese Lung Cancer Society recommended EGFR-TKI over cytotoxic chemotherapy as first-line therapy for patients with EGFR-mutated advanced NSCLC, in alignment with the guidelines from ESMO and NCCN.

CONCLUSION

In conclusion, our findings suggested that treatment with third-generation EGFR-TKI had a tendency to extend PFS in patients with postoperative recurrence of EGFR-mutated NSCLC. Micropapillary components may be a prognostic factor associated with poor OS in these patients. A multi-institutional study...
with a larger sample size is required to confirm our findings and is now under way. A prospective study, which enables us to perform more rigorous analyses, would be the following step.

**SUPPLEMENTARY MATERIAL**

Supplementary material is available at ICVTS online.

**Funding**

No funding.

**Conflict of interest:** none declared.

**Author contributions**

Tetsuji Moriya: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Validation; Writing—original draft; Writing—review & editing. Masatsugu Hamaji: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Resources; Writing—original draft; Writing—review & editing. Akihiko Yoshizawa: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Yoshito Yamada: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Satona Tanaka: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Hideaki Miyamoto: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Naohisa Chiba: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Toshiyuki Miyata: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Ryo Miyata: Conceptualization; Data curation; Investigation; Methodology; Resources; Writing—original draft; Writing—review & editing. Akihiro Ohsumi: Conceptualization; Data curation; Investigation; Methodology. Daisuke Nakajima: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Yojiro Yutaka: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Yoshida Tsumura: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Yoko Otsuka: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Toshiyama Tsuruyama: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing. Tetsuji Moriya: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Validation; Writing—original draft; Writing—review & editing. Masatsugu Hamaji: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Resources; Writing—original draft; Writing—review & editing. Akihiko Yoshizawa: Conceptualization; Data curation; Investigation; Methodology; Writing—review & editing.

**Reviewer information**

Interactive CardioVascular and Thoracic Surgery thanks Mohsen Ibrahim, Mohammad Behgam Shadmehr and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.

**REFERENCES**

[1] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.

[2] Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.

[3] NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (29 April 2021, date last accessed).

[4] Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faire-Finn C et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018 129(Suppl 4): iv192–237.

[5] JLCS Clinical Practice Guidelines in Non-Small Cell Lung Cancer. https://www.haigun.gr.jp/guideline/2019/1/2/190102040100.html?qeq (11 September 2020, date last accessed).

[6] Yokoyama Y, Sonobe M, Yamada T, Sato M, Menju T, Aoyama A et al. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. Int J Clin Oncol 2015;20:1122–9.

[7] Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewsaksulayong B, Lee KH et al. Osimertinib in untreated EGFR-mutated non-small-cell lung cancer. N Engl J Med 2018;378:113–25.

[8] Nishio M, Kato T, Niho S, Yamamoto N, Takahashi T, Nagami N et al. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci 2020;111:1724–38.

[9] Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K et al. A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival and biomarker analysis. J Thorac Oncol 2020;15:91–100.

[10] Noronha V, Pali VM, Joshi A, Menon N, Choquie A, Mahajan A et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol 2020;38:124–36.

[11] Saito H, Futuha T, Furuya N, Watanabe K, Sugawara S, Isawa S et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 2019;20:625–35.

[12] Jeon JH, Kang CH, Kim HS, Seong YW, Park IK, Kim YT. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. Eur J Cardiothorac Surg 2015;47:556–62.

[13] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806–8.

[14] Hickey GL, Dunning J, Seifert B, Sodeck G, Carr MJ, Burger HU et al. EJCTS and ICVTS Editorial Committees. Statistical and data reporting guidelines for the European Journal of Cardiothoracic Surgery and the Interactive Cardiovascular and Thoracic Surgery. Eur J Cardiothorac Surg 2015;48:180–92.

[15] Sonobe M, Yamada T, Sato M, Menju T, Aoyama A, Sato T et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol 2014;21:2546–54.

[16] Sugimura H, Nichols FC, Yang P, Allen MS, Cassidy SD, Deschamps C et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. J Thorac Oncol 2015;10:2409–17.

[17] Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H, Okada M, Toh Y, Doki Y, Endo S et al. Thoracic and cardiovascular surgeries in Japan during 2018: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2021;69:179–212.

[18] Takenaka T, Takenoyama M, Yamaguchi M, Tsyozwara R, Inamasu E, Koji M et al. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. Eur J Cardiothorac Surg 2015;47:550–5.

[19] Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsutsumi J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor: a randomised phase III trial. Lancet Oncol 2010;11:121–8.

[20] Yoshioho H, Shimokawa M, Seto T, Morita S, Yamato Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer: interim analysis of an open-label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.

[21] Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S et al. Solid pre-dominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol 2013;139:1691–700.

[22] Li C, Shen Y, Hu F, Chu T, Yang X, Shao J et al. Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery. Lung Cancer 2020;141:72–7.

[23] Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Fujimoto M, Tsuruyama T et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well
controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer 2013;81:53–9.
[24] Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 2017; 28:1532–9.
[25] Sato M, Watanabe S, Tanaka H, Nozaki K, Arita M, Takahashi M et al. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. PLoS One 2019;14:e0215292.